Conference Proceedings

BEACON CRC (binimetinib [BIM], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)ICTX with

Sanne Huijberts, Jan HM Schellens, Marwan Fakih, Marc Peeters, Scott Kopetz, Axel Grothey, Eric Van Cutsem, Harpreet Singh Wasan, Jayesh Desai, Fortunato Ciardiello, Takayuki Yoshino, Kati Maharry, Ashwin Gollerkeri, Josep Tabernero

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2017